Results 191 to 200 of about 312,758 (261)

Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1. [PDF]

J Virol
Cui W, Wang H, Gao Y, Zhang X, Xin J, Li Z, Li G, Gao W, Zhang W.   +8 more
europepmc   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

In Vitro Anti-HIV-1 Activity of Fucoidans from Brown Algae. [PDF]

Mar Drugs
Nosik MN, Krylova NV, Usoltseva RV, Surits VV, Kireev DE, Shchelkanov MY, Svitich OA, Ermakova SP.   +7 more
europepmc   +1 more source

INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol

BJU International, EarlyView.
Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan, Ethan Senior, Jessica Kendall, Jamie B. Oughton, Fiona Collinson, Jon Griffin, Rachel Hubbard, Steven Kennish, Aidan Noon, Derek J. Rosario, Irbaz B. Riaz, Julie Telliez, James W. F. Catto, Syed A. Hussain   +13 more
wiley   +1 more source

Heptad repeat 1-derived N peptide inhibitors improve broad-spectrum anti-HIV-1 activity. [PDF]

Curr Res Microb Sci
Yuan C, Wang JY, Wang BY, Zhao YL, Li Y, Li D, Ling H, Zhuang M.   +7 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Flux Balance Analysis Reveals Potential Anti-HIV-1 Metabolic Targets. [PDF]

Infect Dis Immun
Han R, Luo F, Yu H, Yan Y, Gong Y, Xie C, Cheng L.   +6 more
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Anti-HIV Activity and Immunomodulatory Properties of Fractionated Crude Extracts of Alternaria alternata. [PDF]

Microorganisms
Kubheka MX, Ndlovu SI, Mkhwanazi NP.
europepmc   +1 more source

Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies. [PDF]

iScience
Fert A, Richard J, Raymond Marchand L, Planas D, Routy JP, Chomont N, Finzi A, Ancuta P.   +7 more
europepmc   +1 more source